Literature DB >> 22820540

Complicated atazanavir-associated cholelithiasis: a report of 14 cases.

Soloniaina Rakotondravelo1, Yves Poinsignon, Françoise Borsa-Lebas, Arnaud de la Blanchardière, Christophe Michau, Hélène Jantzem, Nathalie Massy, Elisabeth Polard, Fanny Giroux, Hélène Kerspern, Ahmed Meskar, Guy Hue, Olivier Tribut, Cédric Arvieux, Pierre Tattevin.   

Abstract

Fourteen human immunodeficiency virus (HIV)-infected patients receiving an atazanavir (ATV)-based antiretroviral regimen developed complicated cholelithiasis. ATV was found in biliary calculi in 8 of 11 cases: infrared spectrometry analysis of calculi revealed that ATV made up a median of 89% (range, 10%-100%) of the total calculus composition. Development and management of ATV-associated cholelithiasis are discussed.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22820540     DOI： 10.1093/cid/cis620

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  7 in total

Review 1.  Antiretroviral therapy: when to start.

Authors:  Christopher J Sellers; David A Wohl
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

2.  Possible Atazanavir-Induced Cholelithiasis in a Pregnant Woman: A Case Report.

Authors:  Claire Bianchi; Kateri Lévesque; Marc Boucher; Ema Ferreira
Journal:  Can J Hosp Pharm       Date:  2016-08-31

3.  PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics.

Authors:  Maria Alvarellos; Chantal Guillemette; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2018-05       Impact factor: 2.089

4.  Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury.

Authors:  Lindsey Devisscher; Mathieu Vinken; Eva Gijbels; Vânia Vilas-Boas; Pieter Annaert; Tamara Vanhaecke
Journal:  Arch Toxicol       Date:  2020-03-10       Impact factor: 5.153

Review 5.  Nanoparticle delivery system, highly active antiretroviral therapy, and testicular morphology: The role of stereology.

Authors:  Edwin Coleridge S Naidu; Samuel Oluwaseun Olojede; Sodiq Kolawole Lawal; Carmen Olivia Rennie; Onyemaechi Okpara Azu
Journal:  Pharmacol Res Perspect       Date:  2021-05

6.  Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy.

Authors:  Kuan-Yin Lin; Sih-Han Liao; Wen-Chun Liu; Aristine Cheng; Shu-Wen Lin; Sui-Yuan Chang; Mao-Song Tsai; Ching-Hua Kuo; Mon-Ro Wu; Hsiu-Po Wang; Chien-Ching Hung; Shan-Chwen Chang
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

7.  Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?

Authors:  Yohei Hamada; Takeshi Nishijima; Hirokazu Komatsu; Katsuji Teruya; Hiroyuki Gatanaga; Yoshimi Kikuchi; Shinichi Oka
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.